局部晚期非小细胞肺癌同步放化疗后不良结局与治疗相关免疫抑制相关
研究回顾性分析155例IIIA/B期局部晚期非小细胞肺癌患者,在同步化疗与调强放疗前后采集白细胞数据。结果显示放疗后三个时间点淋巴细胞和中性粒细胞均显著下降,且放疗后4个月的中性粒细胞及中性粒细胞/淋巴细胞比值与总生存相关,放疗后2个月的淋巴细胞与区域复发相关。
要点
- 同步放化疗后淋巴细胞和中性粒细胞显著下降,提示治疗相关免疫抑制。
- 放疗后4个月中性粒细胞及N/L比值与总生存显著相关。
- 放疗后2个月淋巴细胞与区域复发显著相关。
核心结论
- 局部晚期非小细胞肺癌同步放化疗后白细胞水平显著降低与较差的长期结局相关。
研究设计与样本
- 回顾性收集2004-2014年155例IIIA/B期局部晚期非小细胞肺癌患者同步化疗与调强放疗前后的白细胞数据,放疗中位剂量63 Gy(1.8-2.0 Gy/次)。
主要发现
- 放疗后三个时间点(2周、2个月、4个月)淋巴细胞和中性粒细胞均显著下降(p < 0.0003)。
- 总生存与放疗后4个月的中性粒细胞(p = 0.00001)及中性粒细胞/淋巴细胞比值(p = 0.0003)相关。
- 区域复发与放疗后2个月的淋巴细胞相关(p < 0.0001)。
关键数值与推荐
- 白细胞变量预测总生存或复发需Cox回归和竞争风险分析中p ≤ 0.006(校正9个变量)。
- 白细胞变量与疾病/患者/治疗特征的线性关联需p ≤ 0.005(校正11个特征)。
临床怎么用
- 同步放化疗期间及放疗后监测淋巴细胞和中性粒细胞变化可能有助于识别不良结局高风险患者。
- 治疗相关免疫抑制或为改善局部晚期非小细胞肺癌预后的潜在干预靶点。
局限性
- 为回顾性研究,样本量有限(N = 155)。
- 未发现任何白细胞变量与疾病/患者/治疗特征有统计学显著关联,免疫抑制机制需进一步分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: We test the hypothesis that unsatisfactory outcomes after concurrent chemoradiotherapy (RT) for locally advanced non-small cell lung cancer (LA-NSCLC) are due to treatment-related immunosuppression. MATERIALS AND METHODS: White blood cells (WBCs) data were retrospectively collected for all stage IIIA/B LA-NSCLC patients before and after (after RT: two weeks, two months, four months) concurrent chemotherapy and intensity-modulated RT in which patients were treated to a median of 63 Gy (1.8-2.0 Gy/fractions) in 2004-2014 (N = 155). Nine WBC variables were generated from pre-RT normalized absolute number of lymphocytes and neutrophils (L, N) and the N/L thereof. A WBC variable was considered a predictor for overall survival and recurrence (distant/local/nodal/regional) if p ≤ 0.006 (corrected for 9 variables) from Cox regression and competing risk analyses, respectively; both conducted using bootstrap resampling. Finally, a WBC variable predicting any of the outcomes was linearly associated with each of eleven disease/patient/treatment characteristics (p ≤ 0.005; corrected for 11 characteristics). RESULTS: At the three post-RT time points both L and N significantly decreased (p < 0.0003). Overall survival was associated with N and N/L four months post-RT (p = 0.00001, 0.0003); regional recurrence was associated with L two months post-RT (p < 0.0001). None of the disease/patient/treatment characteristics was significantly associated with any of the three WBC variables that predicted OS or recurrence (lowest p-value: p = 0.006 for tumour stage,). CONCLUSION: Significantly lower WBC levels after concurrent chemo-RT for LA-NSCLC are associated with worse long-term outcomes. The mechanism behind this treatment-related immunosuppression requires further analysis likely including other characteristics as no statistically significant association was established between any WBC variable and the disease/patient/treatment characteristics.
引用
- Thor M, Montovano M, Hotca A, et al. Are unsatisfactory outcomes after concurrent chemoradiotherapy for locally advanced non-small cell lung cancer due to treatment-related immunosuppression? Radiother Oncol. 2019. PMID: 31615633. doi:10.1016/j.radonc.2019.07.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。